Santa Monica, CA, June 01, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical technology
company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6
billion electrophysiology (EP) marketplace, today announced that it will be presenting at the 8th Annual LD Micro Invitational,
which is taking place at the Luxe Sunset Blvd in Bel Air, California on June 4-6. BioSig will be presenting on Monday, June 4
at 10:30AM (PST).
Mr. Kenneth Londoner, Chairman & CEO of BioSig Technologies, Inc., will do a presentation on the Company’s recent progress, the
core value proposition and clinical applications of the Company’s proprietary PURE EPTM System and benefits it aims
to provide to the global and growing market of arrhythmias. Mr. Londoner will also discuss the Company’s recent submission of the
510(k) application to the FDA, as well as other business highlights, including a recent financial update and the Company’s progress
with the global IP strategy. To schedule a one-on-one meeting with BioSig, please contact Natasha Russkina, VP Business Development
and Corporate Finance at nrusskina@biosigtech.com.
About LD Micro
LD Micro was founded in 2006 with the purpose of being an independent newsletter resource in the microcap space. It has since
transformed into several influential conferences annually (Invitational, Summit, and Main Event).
In 2015, LD Micro launched ldmicro.com as a portal to provide exclusive intraday information on the entire sector,
including the first pure microcap index (LDMi) which covers stocks in North America with market capitalizations between
$50-$300m.
About BioSig Technologies
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to
improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of
Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The technology has been
developed to address an unmet need in a large and growing market.
The Company’s first product, PURE EP™ System, is a novel cardiac signal acquisition and display system which is engineered to
assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates
and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and
potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on
technology development and is working toward FDA 510(k) clearance for the PURE EP™ System.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words.
Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various
known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified
and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our
product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed
information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in
the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s
website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events or otherwise.
Contact: Natasha Russkina BioSig Technologies, Inc. VP Business Development & Corporate Finance nrusskina@biosigtech.com +41 (0) 76 823 7527
